1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS

• US 20150344459A1
• Filed: 12/20/2013
• Published: 12/03/2015
• Est. Priority Date: 12/21/2012
• Status: Active Grant

• Current Assignee: Epizyme, Inc. (Ipsen Sa)
• Original Assignee: Epizyme, Inc. (Ipsen Sa)
• Inventors: KUNTZ, KEVIN W., CAMPBELL, JOHN EMMERSON
• Granted Patent: US 9,701,666 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The present invention relates to 1,4-pyridone bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

Claims

1. A compound of Formula (IV) or a pharmaceutically acceptable salt thereof:

3. The compound of claim 1, wherein the compound is of Formula (VI):

4. The compound of claim 1, wherein the compound is of Formula (VIc):

5. The compound of claim 4, wherein R⁷⁰⁶ is sec-butyl, cyclopentyl, or iso-propyl.

6. The compound of claim 1, wherein R₇ is sec-butyl, cyclopentyl, or iso-propyl.

7. The compound of claim 1, wherein R₆ is

8. The compound of claim 1, wherein the compound is Compound 1 or 2, or a pharmaceutically acceptable salt or ester thereof.

9. The compound of claim 3, wherein R₆ is

10. The compound of claim 4, wherein R₆ is

11. The compound of claim 5, wherein R₆ is

12. The compound of claim 6, wherein R₆ is

13. The compound of claim 3, wherein R₇ is sec-butyl, cyclopentyl, or iso-propyl.

14. The compound of claim 3, wherein the compound is Compound 1 or 2, or a pharmaceutically acceptable salt or ester thereof.

15. The compound of claim 4, wherein the compound is Compound 1 or 2, or a pharmaceutically acceptable salt or ester thereof.

16. The compound of claim 5, wherein the compound is Compound 1 or 2, or a pharmaceutically acceptable salt or ester thereof.

17. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

18. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

19. The method of claim 18, wherein the cancer is lymphoma, leukemia or melanoma.

20. The method of claim 18, wherein the cancer is diffuse large B-cell lymphoma (DLBCL), non-Hodgkin'"'"'s lymphoma (NHL), follicular lymphoma or diffuse large B-cell lymphoma, chronic myelogenous leukemia (CML), acute myeloid leukemia, acute lymphocytic leukemia or mixed lineage leukemia, or myelodysplastic syndromes (MDS).

2. A compound of Formula (V) or a pharmaceutically acceptable salt or ester thereof: